A Phase 2/3 interventional study of Zavegepant and Zavegepant matching placebo in Migraine, sponsored by Pfizer. Completed at 82 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-25.
Sponsored by Pfizer · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing zavegepant in Migraine Disorders — 4 open to participants now, 4 under way, none of them phase 3. zavegepant · Migraine Disorders.
Among the 12 studies testing zavegepant in Migraine Disorders, this one has the largest enrollment, is the only one that started in 2019, is one of 3 in phase 2/3, and was the 1st registered.
1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.
Browse Migraine Disorders studies →4 of the 12 studies testing zavegepant in Migraine Disorders are open now, in 1 country. Recruiting first, the newest first:
University of South Florida · Sites in United States
Ages 18+ · Healthy volunteers
Pfizer · Sites in United States
Ages 6–11
Mayo Clinic · Sites in United States
Ages 18+
American Center for Psychiatry and Neurology
Ages 18+
By country, each count listing its studies:
zavegepant: first FDA approval 2023 (ZAVZPRET). What it is approved for, and how studies give it, is on its page →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 6 · Phase 4 2
First in 2019; this study’s year is marked. 1 started in 2019.
This study's enrollment of 2,154 is above the median of 80 across 1,269 interventional studies indexed under Migraine Disorders.
Median enrollment 225 across the 12 interventional studies. Of the 7 that completed or were terminated, 6 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 12 have an industry lead sponsor. The 5 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
47 studies in Migraine Disorders by Pfizer: 10 open now, 14 under way, 6 of them phase 3. Of 30 finished, 24 (80%) have results posted.
Among the 47 studies in Migraine Disorders by Pfizer, this one is the 2nd largest by enrollment of the 37 interventional ones that give a count, is the only one that started in 2019, is one of 5 in phase 2/3, and was the 12th registered.
Pfizer’s Migraine Disorders studies by the year they started, since 2007.
3 of the studies testing zavegepant in Migraine Disorders that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06401642Mayo ClinicEffectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications | 2027-03 |
| NCT07667621University of South FloridaA Prospective, Open-Label Study Evaluating the Effectiveness of Gepants for Acute Treatment of Migraine in the Emergency Department | 2027-07 |
| NCT06995729PfizerA Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine | 2027-08-12 |
Add all 3 to your calendar (.ics) → With an account.
Among the 12 studies testing zavegepant in Migraine Disorders, from their registry updates:
Among Pfizer’s 47 in Migraine Disorders:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the safety and efficacy of three different intranasal dose levels of zavegepant (BHV-3500), relative to placebo, in the acute treatment of moderate to severe migraine.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Key Inclusion Criteria:
Exclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants administered a single intranasal dose of zavegepant 5 mg on occurrence of migraine that reached moderate or severe intensity within 45 days after randomization. The dose was administered using Aptar Unidose System (UDS) liquid spray device.
Drug: Zavegepant · Device: Intranasal Aptar Pharma Unit Dose System
Participants administered a single intranasal dose of zavegepant 10 mg on occurrence of migraine that reached moderate or severe intensity within 45 days after randomization. The dose was administered using Aptar UDS liquid spray device.
Drug: Zavegepant · Device: Intranasal Aptar Pharma Unit Dose System
Participants administered a single intranasal dose of zavegepant 20 mg on occurrence of migraine that reached moderate or severe intensity within 45 days after randomization. The dose was administered using Aptar UDS liquid spray device.
Drug: Zavegepant · Device: Intranasal Aptar Pharma Unit Dose System
Participants administered a single intranasal dose of zavegepant-matching placebo on occurrence of migraine that reached moderate or severe intensity within 45 days after randomization. The dose was administered using Aptar UDS liquid spray device.
Drug: Zavegepant matching placebo · Device: Intranasal Aptar Pharma Unit Dose System
A single dose of zavegepant
Also known as: BHV3500
A single dose of placebo matched to zavegepant
A single-dose intranasal device
Percentage of Participants With Freedom From Pain at 2 Hours Post-dose
Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the electronic clinical outcome assessment (eCOA) handheld device. Pain freedom was defined as pain level of none post-dose.
Time frame: 2 hours post-dose
Percentage of Participants With Freedom From Most Bothersome Symptom (MBS) at 2 Hours Post-dose
MBS was reported as nausea, photophobia, or phonophobia at migraine onset using the eCOA handheld device. Symptom status (absent, present) was assessed post-dose using the eCOA handheld device separately for nausea, photophobia, and phonophobia. Freedom from MBS was defined as MBS reported at on-study migraine attack onset that was absent post-dose.
Time frame: 2 hours post-dose
Percentage of Participants With Pain Relief at 2 Hours Post-dose
Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eCOA handheld device. Pain relief was defined as pain level of none or mild.
Time frame: 2 hours post-dose
Percentage of Participants Who Were Able to Function Normally at 2 Hours Post-dose
Functional disbaility level was assessed on a 4-point scale (normal function, mildly impaired, severely impaired, requires bedrest) using the eCOA handheld device. Normal function was defined as a functional disability level of normal post-dose in the subset of participants with functional disability (mildly impaired, severely impaired, requires bedrest) at on-study migraine attack onset.
Time frame: 2 hours post-dose
Percentage of Participants With Rescue Medication Use Within 24 Hours Post-dose
Participants who did not experience relief of their migraine headache at the end of 2 hours after dosing with study medication (and after the 2-hour assessments had been completed on the eCOA handheld device) were permitted to use the following rescue medications: aspirin, ibuprofen, acetaminophen up to 1000 mg/day (this includes Excedrin® Migraine), naproxen (or any other type of nonsteroidal anti-inflammatory drug), antiemetics (for example, metoclopramide or promethazine), or baclofen. The participant's use of rescue medication was recorded by the site on a case report form.
Time frame: Through 24 hours post-dose
Percentage of Participants With Freedom From Photophobia at 2 Hours Post-dose
Photophobia (sensitivity to light) status was measured as absent or present in the eCOA handheld device. Freedom from photophobia was defined as photophobia absent post-dose in the subset of participants with photophobia present at on-study migraine attack onset.
Time frame: 2 hours post-dose
Percentage of Participants With Freedom From Phonophobia at 2 Hours Post-dose
Phonophobia (sensitivity to sound) status was measured as absent or present in the eCOA handheld device. Freedom from phonophobia was defined as phonophobia absent post-dose in the subset of participants with phonophobia present at on-study migraine attack onset.
Time frame: 2 hours post-dose
Percentage of Participants With Pain Relief at 60 Minutes Post-dose
Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eCOA handheld device. Pain relief was defined as pain level of none or mild.
Time frame: 60 minutes post-dose
Percentage of Participants Who Were Able to Function Normally at 60 Minutes Post-dose
Functional disbaility level was assessed on a 4-point scale (normal function, mildly impaired, severely impaired, requires bedrest) using the eCOA handheld device. Normal function was defined as a functional disability level of normal post-dose in the subset of participants with functional disability (mildly impaired, severely impaired, requires bedrest) at on-study migraine attack onset.
Time frame: 60 minutes post-dose
Percentage of Participants With Pain Relief at 30 Minutes Post-dose
Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eCOA handheld device. Pain relief was defined as pain level of none or mild.
Time frame: 30 minutes post-dose
Percentage of Participants Who Were Able to Function Normally at 30 Minutes Post-dose
Functional disbaility level was assessed on a 4-point scale (normal function, mildly impaired, severely impaired, requires bedrest) using the eCOA handheld device. Normal function was defined as a functional disability level of normal post-dose in the subset of participants with functional disability (mildly impaired, severely impaired, requires bedrest) at on-study migraine attack onset.
Time frame: 30 minutes post-dose
Percentage of Participants With Sustained Pain Relief From 2 to 24 Hours Post-dose
Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eCOA handheld device. Sustained pain relief was defined as pain level of none or mild at 2 hours up to 24 hours post-dose.
Time frame: From 2 hours up to 24 hours post-dose
Percentage of Participants With Sustained Pain Freedom From 2 to 24 Hours Post-dose
Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eCOA handheld device. Sustained pain freedom was defined as pain level of none at 2 hours up to 24 hours post-dose.
Time frame: From 2 hours up to 24 hours post-dose
Percentage of Participants With Sustained Pain Relief From 2 to 48 Hours Post-dose
Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eCOA handheld device. Sustained pain relief was defined as pain level of none or mild at 2 hours up to 48 hours post-dose.
Time frame: From 2 hours up to 48 hours post-dose
Percentage of Participants With Sustained Pain Freedom From 2 to 48 Hours Post-dose
Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eCOA handheld device. Sustained pain freedom was defined as pain level of none at 2 hours up to 48 hours post-dose.
Time frame: From 2 hours up to 48 hours post-dose
Percentage of Participants With Freedom From Nausea at 2 Hours Post-dose
Nausea status was measured as absent or present in the eCOA handheld device. Freedom from nausea was defined as nausea absent post-odse in the subset of participants with nausea present at on-study migraine attack onset.
Time frame: 2 hours post-dose
Percentage of Participants With Pain Relapse From 2 to 48 Hours Post-dose
Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eCOA handheld device. Pain relapse was defined as pain level of mild, moderate, or severe after 2 hours up to 48 hours post-dose in the subset of participants with pain level of none at 2 hours post-dose.
Time frame: From 2 hours up to 48 hours post-dose
The study was conducted at 82 sites in the United States.
| Milestone | Zavegepant 5 mg | Zavegepant 10 mg | Zavegepant 20 mg | Placebo |
|---|---|---|---|---|
| Started | 418 | 417 | 418 | 420 |
| Treated | 388 | 394 | 403 | 403 |
| Modified intent-to-treat (mitt) participants | 387 | 391 | 402 | 401 |
| Completed | 386 | 391 | 399 | 402 |
| Not completed | 32 | 26 | 19 | 18 |
| Withdrew: Adverse event | 1 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 8 | 7 | 4 | 4 |
| Withdrew: Never treated migraine | 19 | 17 | 13 | 12 |
| Withdrew: Pregnancy | 1 | 0 | 0 | 0 |
| Withdrew: Protocol deviation | 2 | 0 | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 1 | 2 | 0 |
| Withdrew: Other than specified | 1 | 0 | 0 | 0 |
Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the electronic clinical outcome assessment (eCOA) handheld device. Pain freedom was defined as pain level of none post-dose.
| percentage of participants | Zavegepant 5 mg | Zavegepant 10 mg | Zavegepant 20 mg | Placebo |
|---|---|---|---|---|
| Percentage of Participants With Freedom From Pain at 2 Hours Post-dose | 19.6 (14.8 to 24.5) | 22.5 (17.5 to 27.6) | 23.1 (18.1 to 28.2) | 15.5 (11.1 to 19.8) |
MBS was reported as nausea, photophobia, or phonophobia at migraine onset using the eCOA handheld device. Symptom status (absent, present) was assessed post-dose using the eCOA handheld device separately for nausea, photophobia, and phonophobia. Freedom from MBS was defined as MBS reported at on-study migraine attack onset that was absent post-dose.
| percentage of participants | Zavegepant 5 mg | Zavegepant 10 mg | Zavegepant 20 mg | Placebo |
|---|---|---|---|---|
| Percentage of Participants With Freedom From Most Bothersome Symptom (MBS) at 2 Hours Post-dose | 39.0 (33.1 to 45.0) | 41.9 (36.0 to 47.9) | 42.5 (36.6 to 48.4) | 33.7 (28.0 to 39.3) |
Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eCOA handheld device. Pain relief was defined as pain level of none or mild.
| percentage of participants | Zavegepant 5 mg | Zavegepant 10 mg | Zavegepant 20 mg | Placebo |
|---|---|---|---|---|
| Percentage of Participants With Pain Relief at 2 Hours Post-dose | 57.9 (51.9 to 63.9) | 60.6 (54.7 to 66.5) | 61.2 (55.4 to 67.0) | 53.6 (47.7 to 59.6) |
Functional disbaility level was assessed on a 4-point scale (normal function, mildly impaired, severely impaired, requires bedrest) using the eCOA handheld device. Normal function was defined as a functional disability level of normal post-dose in the subset of participants with functional disability (mildly impaired, severely impaired, requires bedrest) at on-study migraine attack onset.
| percentage of participants | Zavegepant 5 mg | Zavegepant 10 mg | Zavegepant 20 mg | Placebo |
|---|---|---|---|---|
| Percentage of Participants Who Were Able to Function Normally at 2 Hours Post-dose | 31.7 (25.8 to 37.5) | 34.5 (28.4 to 40.5) | 34.7 (28.8 to 40.6) | 27.4 (21.8 to 32.9) |
Participants who did not experience relief of their migraine headache at the end of 2 hours after dosing with study medication (and after the 2-hour assessments had been completed on the eCOA handheld device) were permitted to use the following rescue medications: aspirin, ibuprofen, acetaminophen up to 1000 mg/day (this includes Excedrin® Migraine), naproxen (or any other type of nonsteroidal anti-inflammatory drug), antiemetics (for example, metoclopramide or promethazine), or baclofen. The participant's use of rescue medication was recorded by the site on a case report form.
| percentage of participants | Zavegepant 5 mg | Zavegepant 10 mg | Zavegepant 20 mg | Placebo |
|---|---|---|---|---|
| Percentage of Participants With Rescue Medication Use Within 24 Hours Post-dose | 24.9 (19.7 to 30.2) | 26.0 (20.7 to 31.4) | 20.2 (15.3 to 25.0) | 27.3 (21.9 to 32.6) |
Photophobia (sensitivity to light) status was measured as absent or present in the eCOA handheld device. Freedom from photophobia was defined as photophobia absent post-dose in the subset of participants with photophobia present at on-study migraine attack onset.
| percentage of participants | Zavegepant 5 mg | Zavegepant 10 mg | Zavegepant 20 mg | Placebo |
|---|---|---|---|---|
| Percentage of Participants With Freedom From Photophobia at 2 Hours Post-dose | 35.0 (28.8 to 41.2) | 35.6 (29.4 to 41.8) | 37.9 (31.7 to 44.0) | 30.4 (24.6 to 36.3) |
Phonophobia (sensitivity to sound) status was measured as absent or present in the eCOA handheld device. Freedom from phonophobia was defined as phonophobia absent post-dose in the subset of participants with phonophobia present at on-study migraine attack onset.
| percentage of participants | Zavegepant 5 mg | Zavegepant 10 mg | Zavegepant 20 mg | Placebo |
|---|---|---|---|---|
| Percentage of Participants With Freedom From Phonophobia at 2 Hours Post-dose | 44.2 (36.9 to 51.6) | 44.8 (37.1 to 52.5) | 43.3 (36.0 to 50.7) | 34.1 (27.2 to 40.9) |
Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eCOA handheld device. Pain relief was defined as pain level of none or mild.
| percentage of participants | Zavegepant 5 mg | Zavegepant 10 mg | Zavegepant 20 mg | Placebo |
|---|---|---|---|---|
| Percentage of Participants With Pain Relief at 60 Minutes Post-dose | 47.0 (41.0 to 53.1) | 46.0 (40.0 to 52.1) | 49.8 (43.8 to 55.7) | 41.9 (36.0 to 47.8) |
Functional disbaility level was assessed on a 4-point scale (normal function, mildly impaired, severely impaired, requires bedrest) using the eCOA handheld device. Normal function was defined as a functional disability level of normal post-dose in the subset of participants with functional disability (mildly impaired, severely impaired, requires bedrest) at on-study migraine attack onset.
| percentage of participants | Zavegepant 5 mg | Zavegepant 10 mg | Zavegepant 20 mg | Placebo |
|---|---|---|---|---|
| Percentage of Participants Who Were Able to Function Normally at 60 Minutes Post-dose | 22.6 (17.3 to 27.8) | 18.9 (13.9 to 23.9) | 18.8 (14.0 to 23.7) | 17.1 (12.4 to 21.8) |
Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eCOA handheld device. Pain relief was defined as pain level of none or mild.
| percentage of participants | Zavegepant 5 mg | Zavegepant 10 mg | Zavegepant 20 mg | Placebo |
|---|---|---|---|---|
| Percentage of Participants With Pain Relief at 30 Minutes Post-dose | 26.6 (21.2 to 32.0) | 29.9 (24.4 to 35.5) | 26.6 (21.3 to 31.9) | 24.7 (19.5 to 29.8) |
Functional disbaility level was assessed on a 4-point scale (normal function, mildly impaired, severely impaired, requires bedrest) using the eCOA handheld device. Normal function was defined as a functional disability level of normal post-dose in the subset of participants with functional disability (mildly impaired, severely impaired, requires bedrest) at on-study migraine attack onset.
| percentage of participants | Zavegepant 5 mg | Zavegepant 10 mg | Zavegepant 20 mg | Placebo |
|---|---|---|---|---|
| Percentage of Participants Who Were Able to Function Normally at 30 Minutes Post-dose | 8.8 (5.3 to 12.4) | 7.6 (4.2 to 11.0) | 9.9 (6.2 to 13.7) | 5.4 (2.6 to 8.2) |
Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eCOA handheld device. Sustained pain relief was defined as pain level of none or mild at 2 hours up to 24 hours post-dose.
| percentage of participants | Zavegepant 5 mg | Zavegepant 10 mg | Zavegepant 20 mg | Placebo |
|---|---|---|---|---|
| Percentage of Participants With Sustained Pain Relief From 2 to 24 Hours Post-dose | 43.7 (37.6 to 49.7) | 42.5 (36.5 to 48.4) | 44.5 (38.6 to 50.5) | 35.7 (29.9 to 41.4) |
Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eCOA handheld device. Sustained pain freedom was defined as pain level of none at 2 hours up to 24 hours post-dose.
| percentage of participants | Zavegepant 5 mg | Zavegepant 10 mg | Zavegepant 20 mg | Placebo |
|---|---|---|---|---|
| Percentage of Participants With Sustained Pain Freedom From 2 to 24 Hours Post-dose | 14.2 (10.0 to 18.5) | 15.1 (10.8 to 19.4) | 15.7 (11.3 to 20.0) | 9.0 (5.6 to 12.4) |
Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eCOA handheld device. Sustained pain relief was defined as pain level of none or mild at 2 hours up to 48 hours post-dose.
| percentage of participants | Zavegepant 5 mg | Zavegepant 10 mg | Zavegepant 20 mg | Placebo |
|---|---|---|---|---|
| Percentage of Participants With Sustained Pain Relief From 2 to 48 Hours Post-dose | 40.1 (34.1 to 46.0) | 39.6 (33.7 to 45.6) | 38.8 (33.0 to 44.6) | 32.7 (27.1 to 38.3) |
Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eCOA handheld device. Sustained pain freedom was defined as pain level of none at 2 hours up to 48 hours post-dose.
| percentage of participants | Zavegepant 5 mg | Zavegepant 10 mg | Zavegepant 20 mg | Placebo |
|---|---|---|---|---|
| Percentage of Participants With Sustained Pain Freedom From 2 to 48 Hours Post-dose | 12.9 (8.8 to 17.0) | 13.8 (9.6 to 18.0) | 13.2 (9.1 to 17.2) | 7.5 (4.3 to 10.6) |
Nausea status was measured as absent or present in the eCOA handheld device. Freedom from nausea was defined as nausea absent post-odse in the subset of participants with nausea present at on-study migraine attack onset.
| percentage of participants | Zavegepant 5 mg | Zavegepant 10 mg | Zavegepant 20 mg | Placebo |
|---|---|---|---|---|
| Percentage of Participants With Freedom From Nausea at 2 Hours Post-dose | 53.2 (45.4 to 60.9) | 53.9 (46.3 to 61.6) | 54.7 (47.4 to 62.0) | 51.0 (43.3 to 58.8) |
Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eCOA handheld device. Pain relapse was defined as pain level of mild, moderate, or severe after 2 hours up to 48 hours post-dose in the subset of participants with pain level of none at 2 hours post-dose.
| percentage of participants | Zavegepant 5 mg | Zavegepant 10 mg | Zavegepant 20 mg | Placebo |
|---|---|---|---|---|
| Percentage of Participants With Pain Relapse From 2 to 48 Hours Post-dose | 31.6 (18.8 to 44.3) | 33.0 (21.0 to 45.0) | 37.6 (25.6 to 49.7) | 50.0 (34.8 to 65.2) |
Collected over Adverse events were assessed from study drug dosing up to the end of the study (up to 52 days).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Zavegepant 5 mg | 0/388 (0%) | 0/388 (0%) | 57/388 (14.7%) |
| Zavegepant 10 mg | 0/394 (0%) | 1/394 (0.3%) | 58/394 (14.7%) |
| Zavegepant 20 mg | 0/403 (0%) | 0/403 (0%) | 81/403 (20.1%) |
| Placebo | 0/403 (0%) | 1/403 (0.2%) | 15/403 (3.7%) |
| Event | Zavegepant 5 mg | Zavegepant 10 mg | Zavegepant 20 mg | Placebo |
|---|---|---|---|---|
| ThrombosisVascular disorders | 0/388 | 1/394 | 0/403 | 0/403 |
| Vestibular migraineNervous system disorders | 0/388 | 0/394 | 0/403 | 1/403 |
| Event | Zavegepant 5 mg | Zavegepant 10 mg | Zavegepant 20 mg | Placebo |
|---|---|---|---|---|
| DysgeusiaNervous system disorders | 54/388 | 53/394 | 65/403 | 14/403 |
| Nasal discomfortRespiratory, thoracic and mediastinal disorders | 5/388 | 5/394 | 21/403 | 1/403 |
Treated Participants included enrolled participants who took study therapy (zavegepant or placebo).
| Age, Continuous(years) | Zavegepant 5 mg | Zavegepant 10 mg | Zavegepant 20 mg | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 41.9 ± 12.58 | 41.3 ± 12.96 | 40.0 ± 12.95 | 40.0 ± 12.07 | 40.8 ± 12.66 |
| Sex: Female, Male(Participants) | Zavegepant 5 mg | Zavegepant 10 mg | Zavegepant 20 mg | Placebo | Total |
|---|---|---|---|---|---|
| Female | 337 | 335 | 344 | 338 | 1354 |
| Male | 51 | 59 | 59 | 65 | 234 |
| Ethnicity (NIH/OMB)(Participants) | Zavegepant 5 mg | Zavegepant 10 mg | Zavegepant 20 mg | Placebo | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 64 | 69 | 72 | 81 | 286 |
| Not Hispanic or Latino | 324 | 325 | 331 | 322 | 1302 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Zavegepant 5 mg | Zavegepant 10 mg | Zavegepant 20 mg | Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 2 | 0 | 3 | 1 | 6 |
| Asian | 17 | 13 | 15 | 13 | 58 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 | 0 | 1 |
| Black or African American | 65 | 74 | 62 | 59 | 260 |
| White | 299 | 297 | 316 | 329 | 1241 |
| More than one race | 5 | 9 | 7 | 1 | 22 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Prophylactic migraine medication use at randomization(Participants) | Zavegepant 5 mg | Zavegepant 10 mg | Zavegepant 20 mg | Placebo | Total |
|---|---|---|---|---|---|
| Yes | 54 | 50 | 57 | 55 | 216 |
| No | 334 | 344 | 346 | 348 | 1372 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Mar 2019 to primary completion in Oct 2019, 7 months.
Results were first posted in Oct 2022, 2 years 11 months after primary completion. A results delay was requested in Sep 2020.
Of 12 phase 2/3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 7 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zavegepant